Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951055 | 0.88 | HRH1 (0.55) | HRH1HRH3ALDH1A1HRH4LMNA | |
| SCHEMBL27679728 | 0.86 | HRH1 (0.53) | HRH1HRH3ALDH1A1HRH4LMNA | |
| SCHEMBL11455318 | 0.84 | HRH1 (0.58) | HRH1HRH3ALDH1A1HRH4LMNA | |
| SCHEMBL28723685 | 0.81 | HTT (0.51) | HRH1HRH3ALDH1A1LMNATAAR1 | |
| SCHEMBL231470 | 0.81 | HRH1 (0.69) | HRH1HRH3ALDH1A1HRH4LMNA | |
| SCHEMBL29485637 | 0.81 | HRH1 (0.69) | HRH1HRH3ALDH1A1HRH4LMNA | |
| SCHEMBL726512 | 0.81 | HRH1 (0.76) | HRH1HRH3ALDH1A1HRH4LMNA | |
| Hydrochloric Acid SCHEMBL841530 | 0.79 | HRH1 (0.67) | HRH1HRH3ALDH1A1HRH4LMNA | |
| SCHEMBL5961501 | 0.79 | HRH1 (0.67) | HRH1HRH3ALDH1A1HRH4LMNA | |
| SCHEMBL4418086 | 0.79 | HRH1 (0.80) | HRH1HRH3ALDH1A1HRH4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371458-A1 | TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY | NUTCRACKER THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-20110021483-A1 | Platinum (IV) Complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2011-01-27 | — | — | US | disclosed |
| EP-2170913-A1 | PLATINUM (IV) COMPLEXES | Platco Technologies (Proprietary) Limited (ZA) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155727-A1 | PLATINUM (IV) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-12-24 | — | — | WO | disclosed |
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371458-A1 | TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY | LNPEP, SLC7A1, APLNR | HRH1 2614/4885HRH3 2157/4885ALDH1A1 4814/4885 |
| US-20110021483-A1 | Platinum (IV) Complexes | OTC, OAT, SLC25A11 | HRH1 3064/4885HRH3 2311/4885ALDH1A1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.